{"id":1628,"date":"2014-10-23T21:15:10","date_gmt":"2014-10-23T21:15:10","guid":{"rendered":"http:\/\/ingelyt.com\/en\/?p=1628"},"modified":"2017-11-14T19:33:33","modified_gmt":"2017-11-14T19:33:33","slug":"dedicated-facilities-versus-multiproduct-facilities","status":"publish","type":"post","link":"http:\/\/ingelyt.com\/en\/blog\/dedicated-facilities-versus-multiproduct-facilities\/","title":{"rendered":"Dedicated facilities versus multiproduct facilities"},"content":{"rendered":"

1. INTRODUCTION<\/strong><\/h2>\n

In pharmaceutical manufacturing plants there is always the doubt related to when it is necessary to have a dedicated facility or when it is possible to manufacture in a same area different products specially when some of them are steroids, sexual hormones, corticoids, cytostatics, high potency, prostaglandins, \u2026<\/p>\n

This lack of definition is understood in different ways for pharmaceutical companies, regulatory agencies, consultants which makes major uncertainty when making the decision about whether it is needed a dedicated facility or not for certain products.<\/p>\n

This uncertainty has a tremendous impact on the investments to be made by a pharmaceutical company as well as in the commercial opportunities developing and manufacturing certain products.<\/p>\n

2.REGULATIONS <\/strong><\/h2>\n

The specific points of the most relevant regulations (EMA, FDA, ICH, WHO and PICs) with regard to compatible products in the manufacturing lines, and to the need to either have or not have dedicated facilities are gathered in the following list<\/p>\n

Europe (EMA)<\/strong><\/p>\n

Eudralex\u00a0 Volume 4 GMP Chapters 3.6 y 5.18<\/p>\n

EMA \/INS \/GMP \/809387 \/2009 Update on revision of Chapter 3 and 5 of the GMP guide “Dedicated facilities”<\/p>\n

USA (FDA)<\/strong><\/p>\n

21 CFR 211.42(d): Separation of facility and equipment<\/p>\n

21 CFR 211.46(d): Separate air handling systems (HVAC)<\/p>\n

21 CFR 211.176: Test for traces of penicillin where possible exposure<\/p>\n

cGMP Guidance for industry non-penicillin beta-lactam drugs<\/p>\n

Guidance Manual Program 7356.002 for Drug Manufacturing Inspections<\/p>\n

ICH<\/strong><\/p>\n

ICH Good manufacturing practice guide for active pharmaceutical ingredients Q7<\/p>\n

WHO(OMS)<\/strong><\/p>\n

Annex 3 WHO Good Manufacturing Practices for Pharmaceutical Products Containing Hazardous Substances<\/p>\n

Annex 2 WHO Good Manufacturing Practices for Active Pharmaceutical Ingredients<\/p>\n

PICS<\/strong><\/p>\n

PICS GMP GUIDE (Part I: Basic Requirements for Medicinal Products) PE 009-10 (PartI)<\/p>\n

3. LACK OF DEFINITION<\/strong><\/h2>\n
    \n
  1. Mixing the GMP concepts directed to protect patients from potential cross contamination with the safety concepts directed to protect operators from the potential exposure<\/li>\n
  2. There are different classifications and criteria (Safebridge, Merck, ISPE, INSHT, \u2026) used to define the potency of a medicine. It is necessary to bear in mind that the GMPs neither define what a high potency product is nor they even refer to any guideline.<\/li>\n
  3. It does not indicate what a dedicated facility is. Many people understand it as a segregated facility which implies an entire dedicated building. But everything indicates that a dedicated facility is directed to the manufacture of a certain typology of product and it can be located in the same building in which other pharmaceutical processes are carried out, providing that there is no risk of cross contamination and providing that there are correct segregation of personal and material flows and HVAC systems; the degree of segregation and protective measures should be defined by the risk analysis<\/li>\n
  4. Simplistic definitions like sexual hormones or cytostatics or steroid, or enclosed terms like some hormones or some steroids \u2026., they are vague definitions that lead to subjective and simplistic conclusions. Decisions must be made in a scientific way product by product, taking into account the tools of risk analysis described in the ICH Q9.<\/li>\n
  5. The lack of definition about exceptional cases, along with campaign manufacture principle, leaves the door open for any company with correct cleaning validation criteria manufacturing these products in a multiproduct facility could be questioned with a negative feedback by any inspector, customer or consultant<\/li>\n<\/ol>\n

    4.TOXICOLOGICAL CRITERIA<\/strong><\/h2>\n

    To try to clarify the topic the EMA published the following document: EMA\/INS\/GMP\/809387\/2009 Update on review of Chapters 3 and 5 of the GMP Guide: \u201cDedicated facilities ” in this document the inspectors’ workgroup GMP\/GDP of the EMA reminded<\/p>\n

      \n
    1. That facilities dedicated in needed for betalactamics antibiotics and when there are manipulated pathogenic alive organisms.<\/li>\n
    2. For the rest of products, the manufacturers when they introduce a new product must evaluate the product and the process to evaluate if it is possible to make of an installation multiproduct. This evaluation must be based on toxicological information of the product. When it is known that the product has a potential risk or is highly powerful or toxic, the authorities supervisors have to be asked.<\/li>\n<\/ol>\n

      5.TOXICOLOGICAL DATA<\/strong><\/h2>\n

      There are three main targets<\/p>\n

        \n
      1. Cleaning validation limits definition<\/li>\n
      2. To check if there is the possibility of manufacturing a product in a multiproduct facility<\/li>\n
      3. To define the risk of cross contamination with the ARL (Acceptable Residual Limit)<\/li>\n<\/ol>\n

        Regulations and guidelines to define toxicological data are:<\/p>\n